1. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses
- Author
-
Preethi Eldi, Tamara H Cooper, Natalie A Prow, Liang Liu, Gary K Heinemann, Voueleng J Zhang, Abigail D Trinidad, Ruth Marian Guzman‐Genuino, Peter Wulff, Leanne M Hobbs, Kerrilyn R Diener, John D Hayball, Eldi, Preethi, Cooper, Tamara H, Prow, Natalie A, Liu, Liang, Heinemann, Gary K, Zhang, Voueleng J, Trinidad, Abigail D, Guzman-Genuino, Ruth Marian, Wulff, Peter, Hobbs, Leanne M, Diener, Kerrilyn R, and Hayball, John D
- Subjects
Immunity, Cellular ,COVID-19 Vaccines ,SARS-CoV-2 ,Vaccination ,Immunology ,COVID-19 ,Cell Biology ,spike ,Antibodies, Viral ,cellular responses ,Antibodies, Neutralizing ,Immunity, Humoral ,Mice ,polyfunctional T cells ,vaccine ,Spike Glycoprotein, Coronavirus ,Vaccinia ,Animals ,Humans ,Immunology and Allergy ,antibodies - Abstract
Refereed/Peer-reviewed The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.
- Published
- 2022